Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic Syndrome
Phase of Trial: Phase II
Latest Information Update: 15 Mar 2017
At a glance
- Drugs Alirocumab (Primary) ; Atorvastatin (Primary)
- Indications Dyslipidaemias
- Focus Therapeutic Use
- 25 Jan 2017 Status changed from active, no longer recruiting to recruiting.
- 13 Jan 2017 Status changed from not yet recruiting to active, no longer recruiting.
- 30 Dec 2016 New trial record